FK506-binding protein 51 (FKBP5) gene polymorphism is not associated with glucocorticoid therapy outcome in patients with idiopathic thrombocytopenic purpura

Lao,Wansheng; Fang,Meiyun; Yang,Xifei

doi:10.3892/mmr.2012.993

FK506-binding protein 51 (FKBP5) gene polymorphism is not associated with glucocorticoid therapy outcome in patients with idiopathic thrombocytopenic purpura

Authors:
- Wansheng Lao
- Meiyun Fang
- Xifei Yang
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaonin 116011, P.R. China , Key Laboratory of Modern Toxicology of Shenzhen, Shenzhen Center for Disease Control and Prevention, Shenzhen 518055, P.R. China
Published online on: July 18, 2012 https://doi.org/10.3892/mmr.2012.993
Pages: 787-790

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The FKBP5 gene codes for the FK506-binding protein 51 (FKBP5), a co-chaperone of hsp90, which regulates glucocorticoid (GC) receptor sensitivity. The FKBP5 gene single nucleotide polymorphisms (SNP), rs1360780, has been found to modulate GC sensitivity in stress-related psychiatric disorders. The aim of the present study was to examine the effects of rs1360780 on the treatment outcome of patients suffering from idiopathic thrombocytopenic purpura (ITP) administered with GC. The polymorphism of FKBP5, rs1360780, was genotyped in 55 GC-resistant ITP patients, 157 GC-sensitive ITP patients and 110 unrelated healthy individuals using real-time PCR and cycling probe technology with DNA extracted from peripheral blood. No significant differences in FKBP5 rs1360780 genotypes (P=0.51) and alleles (P=0.89) were observed between the GC-resistant ITP patients and the healthy controls. There were no significant differences observed between the GC-sensitive ITP patients and the healthy controls (P=0.40 for genotypes and P=0.62 for T allele), as well as between the GC-sensitive ITP patients and the GC-resistant patients (P=0.67 for genotypes and for T allele). The present study demonstrates that the FKBP5 polymorphism may not affect the response of ITP patients to GC treatment.

View Figures

View References

1	Zhou ZP and Yang RC: Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Hematology. 65:21–31. 2008.
2	George JN, Woolf SH and Raskob GE: ITP: practice guideline developed by explicit methods for the American Society of Hematology. Blood. 88:3–40. 1996.PubMed/NCBI
3	Beardsley DS and Ertem M: Platelet autoantibodies in immune thrombocytopenic purpura. Transfus Sci. 9:237–244. 1998. View Article : Google Scholar
4	Kuwana M, Okazaki Y, Kaburaki J and Ikeda Y: Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia. Am J Med. 114:322–325. 2003. View Article : Google Scholar
5	British Committee for Standards in Haematology. General Haematology Task Force: Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 120:574–596. 2003. View Article : Google Scholar : PubMed/NCBI
6	Cines DB and McMillan R: Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med. 56:425–442. 2005. View Article : Google Scholar : PubMed/NCBI
7	Meletis J, Katsandris A, Raptis S and Mantzourani M: Successful treatment of immune thrombocytopenic purpura (ITP) with the thrombopoietin-mimetic romiplostim. Med Sci Monit. 16:100–102. 2010.PubMed/NCBI
8	Kojouri and George JN: Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura. Int J Hematol. 81:119–125. 2005. View Article : Google Scholar : PubMed/NCBI
9	Pierik M, Rutgeerts P, Vlietinck R and Vermeire S: Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol. 12:3657–3667. 2006.PubMed/NCBI
10	Nair SC, Rimerman RA, Toran EJ, Chen S, Prapapanich V and Butts RN: Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. Mol Cell Biol. 17:594–603. 1997.PubMed/NCBI
11	Binder EB: The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology. 34:186–195. 2009. View Article : Google Scholar : PubMed/NCBI
12	Vermeer H, Hendricks-Stegemann BAI, Van der Burg B, van Buul Offers SC and Jansen M: Glucocorticoid-induced increase in lymphocytic FKBP5 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J Clin Endocrin Metabol. 88:277–284. 2003. View Article : Google Scholar
13	Wochnik GM, Ruegg J, Abel GA, Schmidt U, Holsboer F and Rein T: FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem. 28:4609–4616. 2005. View Article : Google Scholar
14	Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, et al: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Gen. 36:1319–1325. 2004. View Article : Google Scholar : PubMed/NCBI
15	Tatro ET, Everall IP, Masliah E, Hult BJ, Lucero G and Chana G: Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. J Neuroimmune Pharmacol. 4:218–226. 2009. View Article : Google Scholar : PubMed/NCBI
16	Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, et al: Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA. 104:15858–15863. 2007. View Article : Google Scholar : PubMed/NCBI
17	Shibuya N, Suzuki A, Sadahiro R, Kamata M, Matsumoto Y, Goto K, Hozumi Y and Otani K: Association study between a functional polymorphism of FK506-binding protein 51 (FKBP5) gene and personality traits in healthy subjects. Neurosci Lett. 485:194–197. 2010. View Article : Google Scholar : PubMed/NCBI
18	Maltese P, Palma L, Sfara C, Rocco PD, Latiano A, Palmieri O, Corritore G, Annese V and Magnani M: Glucocorticoid resistance in Crohn's disease and ulcerative colitis: an association study investigating GR and FKBP5 gene polymorphisms. Pharmacogenomics. 26:1–7. 2011.
19	Scammell JG, Denny WB, Valentine DL and Smith DF: Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticord resistance in three New World primates. Gen Comp Endocrinol. 124:152–165. 2001. View Article : Google Scholar : PubMed/NCBI
20	Hubler TR and Scammell JG: Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids. Cell Stress Chaperones. 9:243–252. 2004. View Article : Google Scholar : PubMed/NCBI
21	Ising M, Depping AM, Siebertz A, Lucae S, Unschuld PG, Kloibers S, Horstmann S, Uhr M, Müller-Myhsok B and Holsboer F: Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci. 28:389–398. 2008. View Article : Google Scholar : PubMed/NCBI
22	Luijk MP, Velders FP, Tharner A, van Ijzendoorn MH, Bakermans-Kranenburg MJ, Jaddoe VW, Hofman A, Verhulst FC and Tiemeieret H: FKBP5 and resistant attachment predict cortisol reactivity in infants: gene-environment interaction. Psychoneuroendocrinology. 35:1454–1461. 2010. View Article : Google Scholar : PubMed/NCBI
23	Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF and Murphy GM Jr: FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet B Neuropsychiatr Genet. 153:554–560. 2010.PubMed/NCBI
24	Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R and Fananas L: Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 104:83–90. 2007. View Article : Google Scholar : PubMed/NCBI